Bezpecné dlouhodobé podávání konvencního amfotericinu B u onkologicky nemocných
[Safety of long-term administration of conventional amphotericin B in oncology patients]
Language Czech Country Czech Republic Media print
Document type Case Reports, English Abstract, Journal Article, Research Support, Non-U.S. Gov't
PubMed
11998223
- MeSH
- Amphotericin B administration & dosage adverse effects MeSH
- Antifungal Agents administration & dosage adverse effects MeSH
- Adult MeSH
- Immunocompromised Host * MeSH
- Kidney drug effects MeSH
- Middle Aged MeSH
- Humans MeSH
- Mycoses drug therapy prevention & control MeSH
- Neoplasms immunology MeSH
- Aged MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- English Abstract MeSH
- Journal Article MeSH
- Case Reports MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Amphotericin B MeSH
- Antifungal Agents MeSH
In cancer patients with persistent fever and neutropenia, amphotericin B is administered for the early treatment and prevention of the clinically occult invasive fungal infections. The major drawback of the conventional amphotericin B is its nephrotoxicity. We have previously showed that massive potassium, sodium, and magnesium supplementation, which corresponds to the amount lost in kidney during amphotericin B administration, as well as vigorous hydration, can markedly reduce nephrotoxicity of conventional amphotericin B. Clinical courses of four oncological patients treated with conventional amphotericin B suspected or proven fungal infection for a period of 24 days (two patients), 39 days, and 47 days are described. During the long-term amphotericin B administration with nephroprotective measures, no severe renal function decrease was observed in any of our patients. Massive ion supplementation corresponding to the amounts lost in kidney, as well as the vigorous hydration are effective in the prevention of the renal function decrease induced by the long-term conventional amphotericin B therapy.